PlainMeds provides educational information only. This is not medical advice. Always consult your doctor or pharmacist.

ticagrelor

Verify with FDA → · CMS NADAC pricing →

Brand names: Brilinta

P2Y12 Inhibitor (Antiplatelet) Rx

Ticagrelor is a drug that helps to prevent blood clots. It is used to lower your risk of heart attack, stroke, and death if you have heart problems.

Drug Pricing (NADAC)

Brand Price

$7.21/unit

Generic Available

Yes (16 manufacturers)

Pricing data from NADAC (CMS), effective December 18, 2024. Compare all drug costs →

What it does

Ticagrelor is used to lower the risk of heart attack, stroke, and cardiovascular death.

Common side effects

Bleeding, Shortness of breath

Key warnings

Ticagrelor can cause serious bleeding, which can sometimes be fatal.

How It Works

Ticagrelor is a P2Y12 inhibitor. This means it blocks a substance in your blood called P2Y12. By blocking P2Y12, ticagrelor helps prevent platelets from sticking together and forming blood clots.

How to Take It

Take ticagrelor exactly as your doctor tells you. For ACS or a history of MI, you'll usually start with a 180 mg dose. Then, you will take 90 mg twice a day for the first year. After one year, your doctor may lower your dose to 60 mg twice a day. For acute ischemic stroke, you'll usually start with a 180 mg dose, then continue with 90 mg twice daily for up to 30 days. Take ticagrelor with 75 to 100 mg of aspirin daily, unless your doctor tells you otherwise.

Pregnancy & Breastfeeding

Tell your doctor if you are pregnant or plan to become pregnant. Animal studies suggest a risk to the fetus. Breastfeeding is not recommended while taking ticagrelor.

Missed Dose

If you miss a dose, take your next dose at the scheduled time. Do not take two doses at once to make up for the missed dose.

Storage

Store ticagrelor tablets at room temperature, between 68°F and 77°F.

Side Effects (from patient reports)

Based on 17,006 FDA adverse event reports.

Shortness of breath
3,952
Heart attack
2,741
Death
1,714
Tiredness
1,525
Using the medicine for something it's not approved for
1,502
Chest pain
1,445
Feeling dizzy
1,223
Bruise
1,066
Interaction with another medicine
929
Weakness
909

FDA Adverse Event Report Analysis

Detailed analysis of 30,895 reports from the FDA Adverse Event Reporting System (FAERS). Reports span 2008–2025.

Total Reports

30,895

Death-Related Reports

3,383

Hospitalization Reports

11,745

Top Indication

Acute Coronary Syndrome

Gender Distribution

Female 10,869 (38%)
Male 17,340 (61%)

Age Distribution

0–17 77
18–44 719
45–64 6,398
65–74 5,090
75+ 3,653

Most Reported Adverse Reactions (FAERS)

# Reaction Reports
1 DYSPNOEA 3,952
2 MYOCARDIAL INFARCTION 2,741
3 DEATH 1,714
4 FATIGUE 1,525
5 OFF LABEL USE 1,502
6 CHEST PAIN 1,445
7 DIZZINESS 1,223
8 CONTUSION 1,066
9 DRUG INTERACTION 929
10 ASTHENIA 909
11 MALAISE 879
12 HAEMORRHAGE 861
13 NAUSEA 836
14 DRUG INEFFECTIVE 830
15 CHEST DISCOMFORT 745

Reactions in Death Reports

DEATH 1,714
MYOCARDIAL INFARCTION 168
CARDIAC ARREST 159
CEREBRAL HAEMORRHAGE 114
DYSPNOEA 110
ACUTE KIDNEY INJURY 95
ACUTE MYOCARDIAL INFARCTION 94
HAEMORRHAGE 92
HAEMORRHAGE INTRACRANIAL 90
GASTROINTESTINAL HAEMORRHAGE 82

Reactions in Hospitalization Reports

MYOCARDIAL INFARCTION 1,571
DYSPNOEA 1,470
CHEST PAIN 882
OFF LABEL USE 657
DRUG INTERACTION 538
ACUTE MYOCARDIAL INFARCTION 528
ACUTE KIDNEY INJURY 522
DIZZINESS 510
RHABDOMYOLYSIS 469
DRUG INEFFECTIVE 437

Source: FDA FAERS (Adverse Event Reporting System) FDA FAERS (Adverse Event Reporting System) Reports are voluntary and do not establish causation

Serious Warnings

Ticagrelor can cause serious bleeding, which can sometimes be fatal. You should not take this medicine if you have active bleeding or a history of bleeding in the brain. Do not start ticagrelor if you are going to have urgent heart bypass surgery (CABG). If possible, manage any bleeding without stopping ticagrelor. Stopping ticagrelor can increase your risk of heart problems.

Known Drug Interactions

Anticoagulants and Antiplatelets Ticagrelor Contraindicated during and 2 weeks after itraconazole treatment.

Mechanism: Itraconazole slows down the breakdown of ticagrelor in your system, which can increase the risk of bleeding.

What to do: You must not take these medications together or within two weeks of stopping your itraconazole treatment.

moderate simvastatin

( 7.3) • Patients receiving more than 40 mg per day of simvastatin or lovastatin may be at increased risk of statin-related adverse effects. 7.4 Simvastatin, Lovastatin , Rosuvastatin Ticagrelor increases serum concentrations of simvastatin and lovastatin because these drugs are metabolized by CYP3A4. Avoid simvastatin and lovastatin doses greater than 40 mg [see Clinical Pharmacology ( 12.3 )].

Mechanism: Ticagrelor slows down how the body breaks down simvastatin. This causes the statin levels to build up in your blood, which can lead to more side effects.

What to do: Do not take more than 40 mg of simvastatin per day while taking this medication. Your doctor may need to lower your statin dose.

moderate lovastatin

( 7.3) • Patients receiving more than 40 mg per day of simvastatin or lovastatin may be at increased risk of statin-related adverse effects. 7.4 Simvastatin, Lovastatin , Rosuvastatin Ticagrelor increases serum concentrations of simvastatin and lovastatin because these drugs are metabolized by CYP3A4. Avoid simvastatin and lovastatin doses greater than 40 mg [see Clinical Pharmacology ( 12.3 )].

Mechanism: Ticagrelor interferes with the way your body processes lovastatin. This can cause the amount of lovastatin in your body to reach unsafe levels.

What to do: Avoid taking more than 40 mg of lovastatin daily. Your doctor will monitor you for side effects and may adjust your dose.

Avoid use of strong inhibitors of CYP3A (e.g., ketoconazole, itraconazole, voriconazole, clarithromycin, nefazodone, ritonavir, saquinavir, nelfinavir, indinavir, atazanavir and telithromycin) [see Clinical Pharmacology ( 12.3 )] .

Mechanism: Ketoconazole blocks the enzyme that breaks down ticagrelor, which can cause the drug to build up to high levels in your body.

What to do: You should avoid taking these two medications together.

Avoid use with strong inducers of CYP3A (e.g., rifampin, phenytoin, carbamazepine and phenobarbital) [see Clinical Pharmacology ( 12.3) ].

Mechanism: Carbamazepine speeds up how fast your body gets rid of ticagrelor, which can make the medicine less effective.

What to do: Avoid using this combination of drugs.

Check all your medications →

Common Questions

Can I crush the ticagrelor tablet?
Yes, if you cannot swallow the tablet whole, you can crush it and mix it with water. You can also give it through a nasogastric tube.
Can I take ticagrelor with other antiplatelet medicines?
No, do not take ticagrelor with other oral P2Y12 platelet inhibitors.
What should I do before surgery?
Talk to your doctor about when to stop taking ticagrelor before surgery. Usually, you will need to stop it for five days before a major surgery.
Can ticagrelor cause shortness of breath?
Yes, some people experience shortness of breath while taking ticagrelor. This is usually mild and goes away on its own.
What dose of aspirin should I take with ticagrelor?
Your doctor will usually prescribe a daily dose of aspirin between 75 mg and 100 mg to take with ticagrelor.
What if I am taking simvastatin or lovastatin?
If you are taking simvastatin or lovastatin, make sure the dose is not higher than 40 mg per day.
Will ticagrelor affect my digoxin levels?
Yes, ticagrelor can affect digoxin levels. Your doctor may monitor your digoxin levels when you start or change your ticagrelor dose.
What should I avoid while taking ticagrelor?
Avoid taking ticagrelor with strong CYP3A inhibitors or CYP3A inducers. Talk to your doctor about any other medicines you are taking.
Can I drink alcohol while taking ticagrelor?
There are no specific warnings about alcohol use with ticagrelor, but it's always best to check with your doctor.
What do I do if I have a bleeding problem?
Tell your doctor immediately if you have any unusual bleeding or bruising while taking ticagrelor.
What are the common side effects of ticagrelor?
The most commonly reported side effects of ticagrelor include Bleeding, Shortness of breath. Based on 17,006 FDA adverse event reports. Always consult your healthcare provider about potential side effects.
Does ticagrelor interact with other medications?
Yes, ticagrelor has 17 known drug interactions. Notable interactions include itraconazole, simvastatin, lovastatin. Always inform your doctor about all medications you are taking.
What drug class is ticagrelor?
ticagrelor belongs to the P2Y12 Inhibitor (Antiplatelet) drug class. It requires a prescription (Rx). Ticagrelor is used to lower the risk of heart attack, stroke, and cardiovascular death.
Is ticagrelor safe during pregnancy?
Tell your doctor if you are pregnant or plan to become pregnant. Animal studies suggest a risk to the fetus. Always consult your healthcare provider before using any medication during pregnancy or breastfeeding.

Related Medications in P2Y12 Inhibitor (Antiplatelet)

Other drugs grouped near ticagrelor — same-class peers and common alternatives.

Compare ticagrelor vs apixaban side-by-side →

Medication Guides

Related Health & Safety Data

Save on ticagrelor

Compare prices and find discounts at pharmacies near you. Free coupons can save up to 80% on prescriptions.

Disclosure: This link may earn us a commission at no extra cost to you. See our terms.

What the FDA Data Shows for ticagrelor

The FDA label for ticagrelor (sold under brand names such as Brilinta) classifies it as a prescription-only medication in the P2Y12 Inhibitor (Antiplatelet) class. Ticagrelor is used to lower the risk of heart attack, stroke, and cardiovascular death. Official labeling lists 2 commonly reported side effects, including Bleeding, Shortness of breath.

Post-market surveillance from the FDA Adverse Event Reporting System (FAERS) captures real-world experience. For this drug, FAERS contains 17,006 voluntary reports. The database also lists 17 documented drug interactions derived from FDA labeling, with the top-flagged interaction rated major severity. NADAC pricing from CMS.

Report counts do not establish causation — a FAERS entry documents a temporal association, not proof that the drug produced the outcome. Widely prescribed medications naturally accumulate more reports than niche therapies, so raw totals must be interpreted alongside total exposure. Shortage status, recall history, and patent information further shape supply and switching decisions. This page summarizes public FDA data for educational purposes only and is not a substitute for professional medical advice — always consult a licensed healthcare provider before starting, stopping, or changing any medication.

Data Sources

Drug labeling: FDA Drug Labels (SPL/DailyMed). Adverse events: FDA Adverse Event Reporting System (FAERS). Pricing: CMS National Average Drug Acquisition Cost (NADAC).

FAERS reports are voluntary and do not establish causation. Drug interactions are derived from FDA labeling and clinical references. Always consult a healthcare professional before making medication decisions.

Last updated: October 28, 2025

All federal data sources used on this page